2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1813 Fixed-duration subcutaneous mosunetuzumab in patients with previously untreated marginal zone lymphoma: 2-year follow-up analysis of the Phase II MorningSun study

Jose C Villasboas, MD, Ian W. Flinn, MD, PhD2, Aung M. Tun, MD3, L. Elizabeth Elizabeth Budde, MD PhD4, Mitul Gandhi, MD5, Tara Graff, DO, MS6, Juliana M. L. Biondo7, Mei Wu, PharmD8, Farah Hossain9, Rona Farighi, PharmD10, Yong Mun, PhD11, Javier L. Munoz, MD, MBA12, Jeff Sharman, MD13, John M. Burke, MD14
1 Mayo Clinic, Rochester, Minnesota, United States
2 Tennessee Oncology and OneOncology, Nashville, Tennessee, United States
3 The University of Kansas Cancer Center, Kansas City, Kansas, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 Virginia Cancer Specialists, Gainesville, Virginia, United States
6 Mission Cancer and Blood, Des Moines, Iowa, United States
7 Genentech, Inc., South San Francisco, California, United States
8 Genentech, Inc., South San Francisco, California, United States
9 Genentech, Inc., South San Francisco, California, United States
10 Genentech, Inc., South San Francisco, California, United States
11 Genentech, Inc., South San Francisco, California, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Willamette Valley Cancer Institute, Eugene, Oregon, United States
14 SCRI at Rocky Mountain Cancer Centers, Aurora, Colorado, United States

Background: Fixed-duration mosunetuzumab, subcutaneous (SC) and intravenous formulations, are approved for relapsed/refractory follicular lymphoma after ≥2 prior lines of therapy. MorningSun (NCT05207670) is an ongoing Phase II basket study, which aims to evaluate the efficacy and safety of mosunetuzumab SC in patients with B-cell non-Hodgkin lymphoma, including previously untreated marginal zone lymphoma (MZL). We report 2-year follow-up data on efficacy and safety of mosunetuzumab SC in patients with untreated MZL overall and by MZL subtype.

Methods: Patients with symptomatic, histologically confirmed MZL (nodal, extranodal [EN], or splenic) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–2 were included. Mosunetuzumab SC was administered with step-up dosing in Cycle (C)1 (Day [D]1, 5mg; D8, 45mg; D15, 45mg), then at 45mg on D1 of each 21-day cycle for 17 cycles. Hospitalization was not required for treatment initiation. The primary endpoint was objective response rate (ORR) by Lugano 2014 criteria (Cheson, et al. J Clin Oncol 2014). Secondary endpoints included complete response (CR), partial response (PR), time-to-response (TTR), duration of complete response (DOCR), progression-free survival (PFS), and safety.

Results: As of February 2, 2026, a total of 36 patients with MZL (nodal, n=18; EN, n=13; splenic, n=5) were enrolled from United States community (n=23) and academic (n=13) sites. Overall, the median age was 69 years (range: 36–81), 55.6% of patients had an ECOG PS of 0, 72.2% had Ann Arbor stage III/IV disease, 30.6% had elevated lactate dehydrogenase levels, and 77.8% had EN involvement. With a median follow-up of 29.3 months (range: 1.5–37.0), 21 (58.3%) patients had completed treatment, with 15 (41.7%) patients discontinuing treatment due to adverse events (AEs; n=6), progressive disease (n=3), physician decision (n=3), withdrawal by patient (n=2), and lost to follow-up (n=1). The median number of treatment cycles received was 17.0 (range: 1–17).

In the overall population, the ORR was 77.8% (CR, 69.4%; PR, 8.3%), with a median TTR of 2.8 months (range: 2.4–5.4). The median duration of response was not reached (NR; 95% confidence interval [CI]: 27.4–not evaluable [NE]) and the median DOCR was NR (95% CI: 27.4–NE). In the nodal, EN, and splenic MZL subtypes, ORRs were 66.7% (CR, 55.6%; PR, 11.1%), 92.3% (CR, 84.6%; PR, 7.7%), and 80.0% (CR, 80.0%; PR, 0%), respectively. The ORR for patients with Ann Arbor stage III/IV disease was 69.2% (CR, 57.7%; PR, 11.5%). Median PFS in the overall population was NR; the 24-month PFS rate was 74.5% (95% CI: 53.2–87.2). All patients experienced ≥1 AE, and 61.1% experienced Grade 3/4 AEs, most commonly neutropenia/decreased neutrophil count (27.8%) and anemia (11.1%). Serious AEs occurred in 38.9% of patients and 16.7% of patients experienced AEs leading to mosunetuzumab discontinuation. No fatal AEs occurred. Cytokine release syndrome (CRS) occurred in 36.1% of patients; all events were Grade 1 (19.4%) or Grade 2 (16.7%), occurred during C1, and resolved. In the nodal, EN, and splenic MZL subtypes, CRS events occurred in 22.2% (n=4/18), 30.8% (n=4/13), and 100% (n=5/5) of patients, respectively. Infections occurred in 83.3% of patients (Grade 2, 61.1%), most commonly COVID-19 (22.2%), and 13.9% experienced a serious infection (all resolved at data cut-off).

Conclusions: Clinically meaningful and durable responses were observed in patients with untreated MZL. The safety profile was manageable, allowing for outpatient administration of fixed-duration mosunetuzumab SC in community practices. These data support further exploration of mosunetuzumab SC in untreated MZL.

Jose C Villasboas, MD: Regeneron Pharmaceuticals, Inc. - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Genentech/Roche - Research Funding; Aptose Biosciences - Research Funding; Enterome - Research Funding; Epizyme - Research Funding; Kite/Gilead - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); TG Therapeutics - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony)